Teacher Retirement System of Texas trimmed its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 6.3% in the 2nd quarter, HoldingsChannel reports. The firm owned 80,013 shares of the biopharmaceutical company’s stock after selling 5,397 shares during the period. Teacher Retirement System of Texas’ holdings in Alexion Pharmaceuticals were worth $9,934,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of the company. Rhumbline Advisers increased its holdings in Alexion Pharmaceuticals by 3.4% in the 2nd quarter. Rhumbline Advisers now owns 408,713 shares of the biopharmaceutical company’s stock worth $50,742,000 after acquiring an additional 13,392 shares in the last quarter. Investment Management of Virginia LLC increased its holdings in Alexion Pharmaceuticals by 74.5% in the 2nd quarter. Investment Management of Virginia LLC now owns 9,125 shares of the biopharmaceutical company’s stock worth $1,133,000 after acquiring an additional 3,895 shares in the last quarter. HMS Capital Management LLC purchased a new stake in Alexion Pharmaceuticals in the 2nd quarter worth $287,000. Nomura Asset Management Co. Ltd. increased its holdings in Alexion Pharmaceuticals by 1.9% in the 2nd quarter. Nomura Asset Management Co. Ltd. now owns 34,433 shares of the biopharmaceutical company’s stock worth $4,275,000 after acquiring an additional 653 shares in the last quarter. Finally, Sei Investments Co. grew its holdings in shares of Alexion Pharmaceuticals by 432.6% during the second quarter. Sei Investments Co. now owns 141,621 shares of the biopharmaceutical company’s stock worth $17,582,000 after buying an additional 115,031 shares in the last quarter. 93.51% of the stock is owned by hedge funds and other institutional investors.

Shares of ALXN stock opened at $116.00 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.27 and a current ratio of 2.72. The stock has a market cap of $26.49 billion, a PE ratio of 22.48, a PEG ratio of 1.15 and a beta of 0.92. Alexion Pharmaceuticals, Inc. has a twelve month low of $102.10 and a twelve month high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.58. The firm had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $976.81 million. Alexion Pharmaceuticals had a negative net margin of 2.68% and a positive return on equity of 15.21%. The company’s revenue was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.56 EPS. analysts forecast that Alexion Pharmaceuticals, Inc. will post 6.46 earnings per share for the current year.

A number of equities research analysts have recently issued reports on the stock. BidaskClub lowered shares of Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $133.00 target price for the company in a report on Tuesday, August 14th. ValuEngine lowered shares of Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 8th. Stifel Nicolaus lowered shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their target price for the stock from $154.00 to $130.00 in a report on Tuesday, August 7th. Finally, Morgan Stanley upped their target price on shares of Alexion Pharmaceuticals from $150.00 to $157.00 and gave the stock an “overweight” rating in a report on Friday, July 27th. Two analysts have rated the stock with a sell rating, two have given a hold rating and seventeen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $157.56.

In other news, EVP John J. Orloff sold 2,115 shares of the business’s stock in a transaction dated Friday, June 8th. The shares were sold at an average price of $118.53, for a total transaction of $250,690.95. Following the transaction, the executive vice president now owns 31,790 shares of the company’s stock, valued at approximately $3,768,068.70. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Paul J. Clancy sold 5,241 shares of the business’s stock in a transaction dated Tuesday, July 10th. The shares were sold at an average price of $131.11, for a total transaction of $687,147.51. Following the transaction, the chief financial officer now directly owns 93,309 shares in the company, valued at approximately $12,233,742.99. The disclosure for this sale can be found here. Insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Featured Story: How to Invest in Marijuana Stocks

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.